公开(公告)号：US20140086906A1

公开(公告)日：2014-03-27

申请号：US13959587

申请日：2013-08-05

Applicant: Xencor, Inc.

Inventor： Matthew J. Bernett ,  Seung Yup Chu ,  John R. Desjarlais ,  Sher Bahadur Karki ,  Gregory Alan Lazar ,  Erik Weiking Pong ,  John O. Richards ,  Eugene Alexander Zhukovsky

IPC: C07K16/28

CPC classification number: C07K16/2896 ,  C07K16/2803 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/72 ,  C07K2317/732 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2317/94

Abstract: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcgγR or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.

Abstract translation: 本发明描述了靶向CD19的抗体，其中所述抗体相对于亲本抗体包含至少一个修饰，其中与亲本抗体相比，修饰改变对FcγγR的亲和力或改变效应子功能。 还公开了使用本发明的抗体的方法。

公开(公告)号：US12234270B2

公开(公告)日：2025-02-25

申请号：US17718087

申请日：2022-04-11

Applicant: Xencor, Inc.

Inventor： Matthew Bernett ,  John R. Desjarlais ,  Rajat Varma ,  Ke Liu ,  Nargess Hassanzadeh-Kiabi ,  Rumana Rashid

IPC: C07K14/54 ,  A61K38/20 ,  A61K47/68 ,  C07K19/00 ,  A61K38/00 ,  C07K1/18

Abstract: The present invention provides novel IL-12 Fc fusion proteins, methods of making and using the same. The IL-12 Fc fusion proteins are useful for treatment of cancer and can be used in combination with checkpoint blockade.

公开(公告)号：US20240417466A1

公开(公告)日：2024-12-19

申请号：US18415608

申请日：2024-01-17

Applicant: Xencor, Inc.

Inventor： John R. Desjarlais ,  Alex Nisthal ,  Michael Hedvat ,  Matthew Adam Dragovich

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  C07K16/30 ,  C07K16/46 ,  C12N15/63

Abstract: Provided herein are novel antigen binding domains and antibodies (e.g., heterodimeric antibodies) that bind Prostate Specific Membrane Antigen (PSMA). In exemplary embodiments, the anti-PSMA antibodies also bind CD3. Such antibodies that bind PSMA and CD3 are useful, for example in the treatment of PSMA-related cancer.

公开(公告)号：US20240400675A1

公开(公告)日：2024-12-05

申请号：US18810362

申请日：2024-08-20

Applicant: Xencor, Inc.

Inventor： Matthew S. Faber ,  Sung-Hyung Lee ,  Yoon Kyung Kim ,  Jing Qi ,  Kendra N. Avery ,  Seung Y. Chu ,  Alex Nisthal ,  Matthew J. Bernett ,  John R. Desjarlais ,  Chad Borchert

IPC: C07K16/28 ,  A61P35/00 ,  C07K16/46 ,  C12N15/63

Abstract: Provided herein are novel CLDN6 binding domains, and anti-CLDN6×anti-CD3 antibodies that include such CLDN6 binding domains. Also provided herein are methods of using such antibodies for the treatment of CLDN6-associated cancers.

公开(公告)号：US20240228608A9

公开(公告)日：2024-07-11

申请号：US18348244

申请日：2023-07-06

Applicant: Xencor, Inc.

Inventor： Matthew S. Faber ,  Sung-Hyung Lee ,  Yoon Kyung Kim ,  Jing Qi ,  Kendra N. Avery ,  Seung Y. Chu ,  Alex Nisthal ,  Matthew J. Bernett ,  John R. Desjarlais ,  Chad Borchert

IPC: C07K16/28 ,  A61P35/00 ,  C07K16/46 ,  C12N15/63

CPC classification number: C07K16/28 ,  A61P35/00 ,  C07K16/2809 ,  C07K16/468 ,  C12N15/63

Abstract: Provided herein are novel CLDN6 binding domains, and anti-CLDN6×anti-CD3 antibodies that include such CLDN6 binding domains. Also provided herein are methods of using such antibodies for the treatment of CLDN6-associated cancers.

公开(公告)号：US20240218082A1

公开(公告)日：2024-07-04

申请号：US18440860

申请日：2024-02-13

Applicant: Xencor, Inc. ,  Janssen Biotech, Inc.

Inventor： John R. Desjarlais ,  Gregory Moore ,  Michael Hedvat ,  Juan Diaz ,  Veronica Gusti Zeng ,  Matthew Adam Dragovich ,  Joseph Erhardt ,  Theresa McDevitt ,  Fouad Moussa ,  Pankaj Seth ,  Fei Shen ,  Adam Zwolak

IPC: C07K16/46 ,  C07K16/28 ,  C07K16/30

CPC classification number: C07K16/468 ,  C07K16/2818 ,  C07K16/3069 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/622

Abstract: Provided herein are novel anti-CD28 x anti-PSMA antibodies and methods of using such antibodies for the treatment of PSMA-associated cancers. Subject anti-CD28 x anti-PSMA antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and PSMA on tumor cells. Thus, such antibodies selectively enhance anti-tumor activity at tumor sites while minimizing peripheral toxicity. The subject antibodies provided herein are particularly useful in combination with other anti-cancer therapies (e.g., anti-CD3 x anti-PSMA antibodies) for the treatment of prostate cancers.

公开(公告)号：US20240132584A1

公开(公告)日：2024-04-25

申请号：US18348244

申请日：2023-07-05

Applicant: Xencor, Inc.

Inventor： Matthew S. Faber ,  Sung-Hyung Lee ,  Yoon Kyung Kim ,  Jing Qi ,  Kendra N. Avery ,  Seung Y. Chu ,  Alex Nisthal ,  Matthew J. Bernett ,  John R. Desjarlais ,  Chad Borchert

IPC: C07K16/28 ,  A61P35/00 ,  C07K16/46 ,  C12N15/63

CPC classification number: C07K16/28 ,  A61P35/00 ,  C07K16/2809 ,  C07K16/468 ,  C12N15/63

Abstract: Provided herein are novel CLDN6 binding domains, and anti-CLDN6×anti-CD3 antibodies that include such CLDN6 binding domains. Also provided herein are methods of using such antibodies for the treatment of CLDN6-associated cancers.

公开(公告)号：US20240059786A1

公开(公告)日：2024-02-22

申请号：US18174370

申请日：2023-02-24

Applicant: Xencor, Inc.

Inventor： John R. Desjarlais ,  Gregory Moore ,  Michael Hedvat ,  Juan Diaz

IPC: C07K16/30 ,  C07K16/28 ,  A61P35/00

CPC classification number: C07K16/30 ,  C07K16/2818 ,  C07K16/2809 ,  A61P35/00 ,  C07K2317/622 ,  C07K2317/31 ,  A61K39/00

Abstract: Provided herein are novel anti-CD28 x anti-TROP2 antibodies and methods of using such antibodies for the treatment of TROP2-associated cancers. Subject anti-CD28 x anti-TROP2 antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and TROP2 on tumor cells. Thus, such antibodies selectively enhance anti-tumor activity at tumor sites while minimizing peripheral toxicity. The subject antibodies provided herein are particularly useful in combination with other anti-cancer therapies, including, for example, bispecific antibodies for the treatment of TROP2-associated cancers.

公开(公告)号：US20230340053A1

公开(公告)日：2023-10-26

申请号：US17968611

申请日：2022-10-18

Applicant: Xencor, Inc.

Inventor： Matthew J. Bernett ,  John R. Desjarlais ,  Rajat Varma ,  Gregory Moore ,  Juan Diaz ,  Alex Nisthal ,  Ke Liu ,  Rumana Rashid ,  Eric Chang

IPC: C07K14/54 ,  C07K16/28 ,  A61P35/00

CPC classification number: C07K14/5443 ,  A61P35/00 ,  C07K16/2851 ,  A61K38/00

Abstract: The present invention is directed to a novel targeted heterodimeric Fc fusion proteins comprising an IL-15/IL,-15Rα Fc fusion protein and an NKG2D antigen binding domain Fc fusion proteins.

公开(公告)号：US20230272114A1

公开(公告)日：2023-08-31

申请号：US18087157

申请日：2022-12-22

Applicant: Xencor, Inc.

Inventor： John R. Desjarlais ,  Seung Y. Chu ,  Holly M. Horton ,  Matthew J. Bernett

IPC: C07K16/42 ,  A61P37/08 ,  C07K16/46

CPC classification number: C07K16/4291 ,  A61P37/08 ,  C07K16/464 ,  C07K2317/24 ,  C07K2317/92 ,  C07K2317/52 ,  C07K2317/76 ,  A61K2039/505

Abstract: The present invention relates to immunoglobulins that bind IgE and FcγRIIb with high affinity, said compositions being capable of inhibiting cells that express membrane-anchored IgE. Such compositions are useful for treating IgE-mediated disorders, including allergies and asthma.